Maryland Polycystic Kidney Disease Research and Translation Core Center (MPKD-RTCC)

马里兰州多囊肾病研究与转化核心中心 (MPKD-RTCC)

• 批准号: 10894547
• 负责人: Terry J Watnick
• 金额: $ 6.62万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-24 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10894547
• 关键词: Address; Antibodies; Baltimore; Basic Science; Biomedical Research; Cell Culture Techniques; Clinical; Collaborations; Communities; Country; Discipline; Goals; Inherited; Institution; Kidney Failure; Maryland; Mission; National Institute of Diabetes and Digestive and Kidney Diseases; Polycystic Kidney Diseases; Reagent; Research; Research Personnel; Resources; Science; Stretching; Translational Research; Translations; Universities; base; biobank; cellular engineering; clinical investigation; experience; innovation; interdisciplinary collaboration; medical schools; mouse model; prevent; vector

Project Summary In this application we establish the Maryland Polycystic Kidney Disease (PKD) Research and Translation Core Center (MPKD-RTCC). The mission of this Center is to facilitate translational and basic research in the field of polycystic kidney disease and related disciplines by providing unique resources, reagents and expertise to a broad base of investigators. This proposal capitalizes on a long tradition of PKD research by MPKD-RTCC investigators who have been at the forefront of PKD science for the past two decades. The Center consists of 4 highly collaborative and integrated biomedical research cores that together will distribute an essential “toolbox” of reagents and expertise tailored specifically to PKD research. The MPKD-RTCC cores include 1) Antibody and Vector 2) Mouse Models and Biobank 3) Cell Culture and Engineering and 4) Clinical and Translation. Each core addresses a critical need in the PKD research pipeline, stretching from basic to clinical investigation. In addition, MPKD-RTCC core leaders will pioneer solutions to perceived needs among PKD Researchers by expanding in innovative directions. We expect that this strategy will continue our proven track record of supporting high impact science across the country. These activities will be organized by an Administrative Core led by two experienced investigators who will leverage the resources of two outstanding research institutions in Baltimore, the University of Maryland Baltimore (UMB) and the Johns Hopkins School of Medicine. As a team they will drive the MPKD-RTCC’s fundamental commitment to the principle of collaborative science by streamlining SOPs for sharing high quality reagents and expertise, by integrating our the core’s activities and by coordinating collaboration with other RTCCs within the PKD Research Consortium. The Center’s Specific Aims are: 1) To provide critical state of the art reagents and expertise to a national group of PKD investigators 2) To provide critical state of the art reagents and expertise to non-PKD investigators in order to remove barriers to PKD related research 3) To develop innovative reagents and resources that will advance biomedical discoveries in the field of PKD 4) To drive collaboration between MPKD-RTCC Cores and other RTCCs within the PKD Research Consortium and 5) To partner with other RTCCs, the consortium steering committee including the NIDDK to achieve the overall goals of the PKD Research Consortium. Through expanded interdisciplinary collaborations, we hope to catalyze the translation of biomedical discoveries that will prevent progression of polycystic kidney disease and its consequences.

项目摘要 在本申请中，我们建立了马里兰州多囊肾病（PKD）研究和翻译核心 中心（MPKD-RTCC）。该中心的使命是促进翻译和基础研究领域的 多囊肾疾病和相关学科提供独特的资源，试剂和专业知识， 广泛的调查人员基础。这项建议利用了MPKD-RTCC对PKD研究的悠久传统 在过去的二十年里，研究人员一直处于PKD科学的前沿。该中心由 4个高度协作和集成的生物医学研究核心，共同分发一个重要的 专门为PKD研究量身定制的试剂和专业知识的“工具箱”。MPKD-RTCC内核包括1） 抗体和载体2）小鼠模型和生物库3）细胞培养和工程化和4）临床和 翻译.每个核心解决了PKD研究管道中的关键需求，从基础到临床 调查此外，MPKD-RTCC核心领导人将率先解决PKD中的感知需求 研究人员通过向创新方向扩展。我们预计，这一战略将继续我们行之有效的轨道 支持全国高影响力科学的记录。这些活动将由一个 由两名经验丰富的调查员领导的行政核心，他们将利用两名杰出的 研究机构在巴尔的摩，马里兰州大学巴尔的摩（UMB）和约翰霍普金斯学校 医学。作为一个团队，他们将推动MPKD-RTCC对以下原则的基本承诺： 通过简化SOP共享高质量的试剂和专业知识，通过整合我们的 通过协调与PKD研究联盟内其他RTCC的合作， 该中心的具体目标是：1）为国家小组提供最先进的试剂和专业知识 2）为非PKD研究者提供关键的最新试剂和专业知识， 为了消除PKD相关研究的障碍3）开发创新的试剂和资源， 推进PKD领域的生物医学发现4）推动MPKD-RTCC核心和 PKD研究联盟内的其他RTCC; 5）为了与其他RTCC合作，联盟 指导委员会，包括NIDDK，以实现PKD研究联盟的总体目标。 通过扩大跨学科合作，我们希望促进生物医学的翻译， 这些发现将预防多囊肾病的进展及其后果。

项目成果

The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression.

• DOI: 10.1172/jci.insight.154773
• 发表时间: 2023-01-10
• 期刊: JCI INSIGHT
• 影响因子: 8
• 作者: Nguyen, Dustin T.;Kleczko, Emily K.;Dwivedi, Nidhi;Monaghan, Marie-Louise T.;Gitomer, Berenice Y.;Chonchol, Michel B.;Clambey, Eric T.;Nemenoff, Raphael A.;Klawitter, Jelena;Hopp, Katharina
• 通讯作者: Hopp, Katharina

A genetic screen in Drosophila reveals an unexpected role for the KIP1 ubiquitination-promoting complex in male fertility.

• DOI: 10.1371/journal.pgen.1009217
• 发表时间: 2020-12
• 期刊: PLoS genetics
• 影响因子: 4.5
• 作者: Li W;Liang J;Outeda P;Turner S;Wakimoto BT;Watnick T
• 通讯作者: Watnick T

Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).

• DOI: 10.1016/j.kint.2021.06.013
• 发表时间: 2021-09
• 期刊: Kidney international
• 影响因子: 19.6
• 作者: Perrone RD;Abebe KZ;Watnick TJ;Althouse AD;Hallows KR;Lalama CM;Miskulin DC;Seliger SL;Tao C;Harris PC;Bae KT
• 通讯作者: Bae KT

Role of chemokines, innate and adaptive immunity.

• DOI: 10.1016/j.cellsig.2020.109647
• 发表时间: 2020-09
• 期刊: Cellular signalling
• 影响因子: 4.8
• 作者: Zimmerman KA;Hopp K;Mrug M
• 通讯作者: Mrug M

Resident Macrophages in Cystic Kidney Disease.

• DOI: 10.34067/kid.0006052020
• 发表时间: 2021-01-28
• 期刊: Kidney360
• 作者: Li Z;Zimmerman KA;Yoder BK
• 通讯作者: Yoder BK